metformin has been researched along with carboplatin in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (60.00) | 24.3611 |
| 2020's | 8 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirsch, HA; Iliopoulos, D; Struhl, K | 1 |
| Eucker, J; Habbel, P; Liu, H; Possinger, K; Regierer, AC; Schefe, JH; Scholz, C; Schulz, CO; Zang, C | 1 |
| Alonso, C; Barra, A; Barriga, MI; Brañes, J; Bravo, E; Bravo, ML; Bustamente, E; Cuello, MA; Erices, R; Garrido, M; Gonzalez, P; Ibañez, C; Kato, S; Oliva, B; Owen, GI; Pizarro, J; Racordon, D | 1 |
| Amant, F; Cattaneo, A; Coenegrachts, L; Hermans, E; Lambrechts, D; Schrauwen, S | 1 |
| Berbée, M; Buijsen, J; Houben, R; Janssen, L; Lambin, P; Larue, R; Schraepen, MC; Sosef, M; Van De Voorde, L; Vanneste, B | 1 |
| Kumar, L; Patel, S; Singh, N | 1 |
| Anderegg, MC; Gisbertz, SS; Hulshof, MC; Lagarde, SM; Meijer, SL; Spierings, LE; van Berge Henegouwen, MI; van Laarhoven, HW; van Oijen, MG; Wilmink, JW | 1 |
| Abo-Elmatty, DM; Ahmed, EA; Helmy, SA; Tawfik, MK | 1 |
| Brahmer, JR; Coleman, B; Ettinger, DS; Forde, PM; Gabrielson, E; Hann, CL; Kelly, RJ; Marrone, KA; Purtell, M; Rosner, GL; Zhou, X | 1 |
| Dahlberg, SE; Kravets, S | 1 |
| Cai, H; Everett, RS; Thakker, DR | 1 |
| Liu, Y; Sun, H; Zhang, H; Zheng, Y; Zhu, J | 1 |
| Broekman, KE; Gietema, JA; Hof, MAJ; Jalving, M; Lefrandt, JD; Nijman, HW; Reyners, AKL; Touw, DJ | 1 |
| Chou, PC; Huang, CF; Lee, MH; Lin, JH; Sung, PL; Wen, KC; Wu, ATH; Yeung, SJ | 1 |
| Han, JY; Joo, J; Kim, MJ; Kim, SY; Kim, TS; Lee, EK; Lee, JS; Lee, SH; Lee, Y; Lee, YJ; Park, M; Park, S; Wie, GA | 1 |
| Banz-Jansen, C; Burghardt, L; Förster, C; Helweg, LP; Kaltschmidt, B; Kaltschmidt, C; Storm, J; Wethkamp, N; Wilkens, L; Windmöller, BA | 1 |
| Tossetta, G | 1 |
| Duarte, D; Nunes, M; Ricardo, S; Vale, N | 1 |
| Chitikela, S; Gupta, Y; Jain, D; Khurana, S; Kumar, S; Malik, PS; Pushpam, D; Singh, V; Verma, S | 1 |
| Ayhan, S; Caydere, M; Gozukucuk, M; Guney, G; Guney, SS; Hancerliogullari, N; Tokmak, A; Ustun, Y | 1 |
1 review(s) available for metformin and carboplatin
| Article | Year |
|---|---|
Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Diabetes Mellitus, Type 2; Female; Humans; Metformin; Ovarian Neoplasms; Paclitaxel | 2022 |
5 trial(s) available for metformin and carboplatin
| Article | Year |
|---|---|
A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2018 |
Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor I; Metformin; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Progression-Free Survival; Prospective Studies; Signal Transduction | 2019 |
Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Metformin; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2020 |
Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diet; Disease-Free Survival; Humans; Lung Neoplasms; Metformin | 2021 |
A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Metformin; Pemetrexed | 2023 |
14 other study(ies) available for metformin and carboplatin
| Article | Year |
|---|---|
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Humans; Injections, Intraperitoneal; Lung Neoplasms; Male; Metformin; Mice; Mice, Nude; Neoplasms; Paclitaxel; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Autophagy; Breast Neoplasms; Carboplatin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Everolimus; Female; Humans; Metformin; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells.
Topics: Antineoplastic Agents; Carboplatin; Cell Cycle; Cell Line, Tumor; Cell Survival; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Hypoglycemic Agents; Metformin; Ovarian Neoplasms; Time Factors; Tumor Cells, Cultured | 2013 |
The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Endometrial Neoplasms; Female; Humans; Metformin; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2015 |
Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Diabetes Mellitus, Type 2; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Hypoglycemic Agents; Logistic Models; Male; Metformin; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Metformin and epithelial ovarian cancer therapeutics.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Metformin; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2015 |
Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Salvage Therapy; Survival Rate | 2015 |
Metformin enhancing the antitumor efficacy of carboplatin against Ehrlich solid carcinoma grown in diabetic mice: Effect on IGF-1 and tumoral expression of IGF-1 receptors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Carcinoma, Ehrlich Tumor; Caspase 3; Cell Line, Tumor; Cell Proliferation; Diabetes Mellitus, Experimental; Drug Synergism; Female; Humans; Insulin-Like Growth Factor I; Intercellular Signaling Peptides and Proteins; Metformin; Mice; Mice, Inbred Strains; Neovascularization, Pathologic; Receptor, IGF Type 1; Vascular Endothelial Growth Factor A | 2017 |
Interpretation of Results from Under-accruing Studies.
Topics: Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Metformin; Paclitaxel | 2018 |
Efficacious dose of metformin for breast cancer therapy is determined by cation transporter expression in tumours.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Drug Synergism; Female; Humans; Hypoglycemic Agents; Mammary Neoplasms, Experimental; Metformin; Mice, Nude; Organic Cation Transport Proteins; Paclitaxel; Tumor Burden | 2019 |
Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Carboplatin; Drug Synergism; Female; Humans; Metformin; Mice; Neoadjuvant Therapy; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Xenograft Model Antitumor Assays | 2020 |
The Diminishment of Novel Endometrial Carcinoma-Derived Stem-like Cells by Targeting Mitochondrial Bioenergetics and MYC.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Endometrial Neoplasms; Energy Metabolism; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Metformin; Mitochondria; Neoplastic Stem Cells; Proto-Oncogene Proteins c-myc; Pyridines; Signal Transduction | 2022 |
The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cell Line, Tumor; Drug Synergism; Humans; Metformin; Neoplasm Recurrence, Local; Paclitaxel | 2022 |
Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
Topics: Animals; Anti-Mullerian Hormone; Carboplatin; Catalase; Female; Malondialdehyde; Metformin; Ovarian Reserve; Rats | 2023 |